Immunocore (NASDAQ:IMCR - Free Report) had its price objective decreased by Mizuho from $90.00 to $88.00 in a report released on Monday, Benzinga reports. Mizuho currently has a buy rating on the stock.
Other research analysts have also recently issued research reports about the stock. HC Wainwright increased their target price on shares of Immunocore from $90.00 to $100.00 and gave the stock a buy rating in a report on Thursday. Guggenheim restated a buy rating and set a $92.00 price objective on shares of Immunocore in a research note on Tuesday, April 23rd. Canaccord Genuity Group lifted their target price on Immunocore from $63.00 to $67.00 and gave the company a hold rating in a research report on Thursday. Leerink Partnrs reissued an outperform rating on shares of Immunocore in a research report on Monday, April 29th. Finally, SVB Leerink started coverage on Immunocore in a research report on Monday, April 29th. They set an outperform rating and a $74.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Immunocore presently has a consensus rating of Moderate Buy and a consensus price target of $81.85.
Get Our Latest Analysis on Immunocore
Immunocore Stock Down 3.3 %
IMCR stock traded down $1.96 during trading hours on Monday, reaching $56.99. 745,765 shares of the stock were exchanged, compared to its average volume of 476,559. The company has a market cap of $2.84 billion, a price-to-earnings ratio of -46.71 and a beta of 0.92. The firm's 50-day moving average is $60.44 and its 200-day moving average is $61.63. Immunocore has a 12 month low of $42.21 and a 12 month high of $76.98. The company has a debt-to-equity ratio of 1.22, a current ratio of 5.96 and a quick ratio of 5.94.
Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.12). Immunocore had a negative return on equity of 16.54% and a negative net margin of 22.60%. The firm had revenue of $70.30 million for the quarter, compared to the consensus estimate of $70.72 million. During the same quarter in the previous year, the business posted ($0.35) earnings per share. The firm's quarterly revenue was up 27.6% compared to the same quarter last year. On average, equities research analysts expect that Immunocore will post -1.77 earnings per share for the current year.
Institutional Investors Weigh In On Immunocore
A number of hedge funds and other institutional investors have recently modified their holdings of IMCR. Legato Capital Management LLC grew its holdings in shares of Immunocore by 61.7% during the 4th quarter. Legato Capital Management LLC now owns 7,235 shares of the company's stock worth $494,000 after purchasing an additional 2,762 shares in the last quarter. Graham Capital Management L.P. bought a new stake in shares of Immunocore during the 3rd quarter worth $411,000. Qube Research & Technologies Ltd boosted its stake in Immunocore by 102.0% in the third quarter. Qube Research & Technologies Ltd now owns 125,199 shares of the company's stock valued at $6,498,000 after buying an additional 63,232 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Immunocore by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company's stock worth $181,000 after acquiring an additional 674 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Immunocore by 4.4% in the third quarter. FMR LLC now owns 2,136,223 shares of the company's stock worth $110,870,000 after acquiring an additional 90,116 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.
About Immunocore
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Read More
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
